Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours

OBJECTIVES: The optimal combination of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and chemotherapy has helped to improve therapeutic effects in non-small-cell lung cancer (NSCLC). This study aimed to explore the progression free survival (PFS) of patients after sequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue-Yun, Chen, Ye, Hong, Yang, Fu, Qing, Li, Pan-Pan, Lin, Zhen-Yu, Ding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852816/
https://www.ncbi.nlm.nih.gov/pubmed/31450915
http://dx.doi.org/10.31557/APJCP.2019.20.8.2415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852816/
https://www.ncbi.nlm.nih.gov/pubmed/31450915
http://dx.doi.org/10.31557/APJCP.2019.20.8.2415

Ejemplares similares